OpenAlex
PricingAboutJobs
Log inGet started
Work

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

HTML

Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2016.34.15_suppl.510
Authors: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortes, Véronique Diéras, Debra A. Patt, Hans Wildiers, Martin Frenzel, Andrew Koustenis, Jose Baselga
Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Vall d'Hebron Institute of Oncology, Institut Curie, Texas Oncology, KU Leuven, Eli Lilly (United States)
Language: English

Topic: Advanced Breast Cancer Therapies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: abemaciclib, CDK4/6 inhibitors, hormone receptor-positive HER2-negative breast cancer, metastatic breast cancer, monotherapy, objective response rate, progression-free survival, treatment-emergent adverse events, chemotherapy-refractory disease, diarrhea, fatigue, nausea
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2665075838
Cites:
Cited by: 71
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security